Standard BioTools (LAB) Competitors $1.61 +0.10 (+6.62%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LAB vs. ADPT, PACB, TRNS, CTKB, EYPT, QTRX, AEHR, NAUT, QSI, and SENSShould you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include Adaptive Biotechnologies (ADPT), Pacific Biosciences of California (PACB), Transcat (TRNS), Cytek Biosciences (CTKB), EyePoint Pharmaceuticals (EYPT), Quanterix (QTRX), Aehr Test Systems (AEHR), Nautilus Biotechnology (NAUT), Quantum-Si (QSI), and Senseonics (SENS). Standard BioTools vs. Adaptive Biotechnologies Pacific Biosciences of California Transcat Cytek Biosciences EyePoint Pharmaceuticals Quanterix Aehr Test Systems Nautilus Biotechnology Quantum-Si Senseonics Standard BioTools (NASDAQ:LAB) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, community ranking, earnings and analyst recommendations. Which has more volatility and risk, LAB or ADPT? Standard BioTools has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Is LAB or ADPT more profitable? Standard BioTools has a net margin of -79.92% compared to Adaptive Biotechnologies' net margin of -110.13%. Standard BioTools' return on equity of -27.05% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Standard BioTools-79.92% -27.05% -15.52% Adaptive Biotechnologies -110.13%-62.06%-26.82% Do insiders & institutionals believe in LAB or ADPT? 53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 53.1% of Standard BioTools shares are held by insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in LAB or ADPT? Adaptive Biotechnologies received 89 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 57.32% of users gave Adaptive Biotechnologies an outperform vote. CompanyUnderperformOutperformStandard BioToolsOutperform Votes5100.00% Underperform VotesNo VotesAdaptive BiotechnologiesOutperform Votes9457.32% Underperform Votes7042.68% Which has stronger valuation and earnings, LAB or ADPT? Standard BioTools has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStandard BioTools$106.34M5.64-$74.66M-$0.71-2.27Adaptive Biotechnologies$170.28M3.83-$225.25M-$1.34-3.30 Does the media prefer LAB or ADPT? In the previous week, Adaptive Biotechnologies had 12 more articles in the media than Standard BioTools. MarketBeat recorded 13 mentions for Adaptive Biotechnologies and 1 mentions for Standard BioTools. Adaptive Biotechnologies' average media sentiment score of 0.81 beat Standard BioTools' score of 0.63 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer LAB or ADPT? Standard BioTools currently has a consensus price target of $2.88, indicating a potential upside of 78.57%. Adaptive Biotechnologies has a consensus price target of $6.50, indicating a potential upside of 47.06%. Given Standard BioTools' stronger consensus rating and higher probable upside, research analysts plainly believe Standard BioTools is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Standard BioTools 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryStandard BioTools beats Adaptive Biotechnologies on 12 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Standard BioTools News Delivered to You Automatically Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LAB vs. The Competition Export to ExcelMetricStandard BioToolsAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$562.11M$5.08B$5.05B$8.87BDividend YieldN/A0.46%4.97%4.06%P/E Ratio-2.2710.7497.3414.18Price / Sales5.643.901,218.4289.42Price / CashN/A40.5933.5132.79Price / Book1.232.405.805.12Net Income-$74.66M$515,312.50$119.07M$225.99M7 Day Performance-5.29%-5.56%-1.83%-1.32%1 Month Performance-14.36%-8.12%-3.64%0.60%1 Year Performance-30.00%-17.04%31.62%26.23% Standard BioTools Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABStandard BioTools3.2161 of 5 stars$1.61+6.6%$2.88+78.6%-29.1%$562.11M$106.34M-2.27620ADPTAdaptive Biotechnologies4.3927 of 5 stars$4.42-1.3%$6.50+47.1%-0.5%$652.30M$170.28M-3.30709Short Interest ↓Analyst RevisionPACBPacific Biosciences of California1.846 of 5 stars$1.72flat$3.63+110.8%-80.0%$471.05M$200.52M0.00730Analyst RevisionTRNSTranscat2.9594 of 5 stars$102.83-1.4%$127.25+23.7%+7.5%$959.21M$259.48M51.931,104Positive NewsCTKBCytek Biosciences3.2393 of 5 stars$6.13flat$9.17+49.5%+0.8%$789.61M$201.21M-76.63500Short Interest ↓EYPTEyePoint Pharmaceuticals2.4787 of 5 stars$8.96-2.8%$28.00+212.7%+26.6%$628.59M$46.02M0.00120QTRXQuanterix2.4262 of 5 stars$11.02-0.4%$23.25+111.0%-52.5%$424.47M$122.37M0.00460AEHRAehr Test Systems2.1758 of 5 stars$11.27+1.0%$25.00+121.8%-56.6%$333.93M$66.22M11.3990NAUTNautilus Biotechnology1.7398 of 5 stars$2.34+4.5%$4.50+92.3%-15.8%$293.82MN/A-4.18130QSIQuantum-Si2.5603 of 5 stars$1.39+120.6%$2.50+79.9%-12.0%$197.88M$2.27M-2.17150Options VolumeAnalyst RevisionGap UpHigh Trading VolumeSENSSenseonics1.5924 of 5 stars$0.32+3.2%$2.00+519.8%-45.2%$188.28M$22.39M0.0090Gap Down Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Pacific Biosciences of California Alternatives Transcat Alternatives Cytek Biosciences Alternatives EyePoint Pharmaceuticals Alternatives Quanterix Alternatives Aehr Test Systems Alternatives Nautilus Biotechnology Alternatives Quantum-Si Alternatives Senseonics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LAB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LAB Stock Alerts